Life
Analysis of Drug Pricing Reforms and Gilead's New Deal
Recent comments from a senior health official during the Trump administration reveal critical flaws in the proposed most-favored nation drug pricing plan, alongside insights into Gilead's latest deal.
Editorial Staff 13 days ago